Tim Anderson
Stock Analyst at Bank of America Securities
(4.42)
# 1,184
Out of 4,988 analysts
257
Total ratings
63.2%
Success rate
12.5%
Average return
Main Sectors:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Reiterated: Buy | $248 → $282 | $257.12 | +9.68% | 22 | Sep 8, 2026 | |
| AARD Aardvark Therapeutics | Reiterated: Buy | $25 | $5.29 | +373.04% | 7 | Dec 18, 2025 | |
| AMLX Amylyx Pharmaceuticals | Reiterated: Buy | $16 → $15 | $31.62 | -52.56% | 3 | Dec 18, 2025 | |
| MLYS Mineralys Therapeutics | Reiterated: Buy | $43 → $46 | $29.34 | +56.78% | 8 | Dec 18, 2025 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $950 → $1,286 | $1,115.70 | +15.26% | 36 | Dec 1, 2025 | |
| MRK Merck & Co. | Reiterated: Buy | $98 → $105 | $143.93 | -27.05% | 29 | Nov 17, 2025 | |
| MRNA Moderna | Reiterated: Sell | $24 → $21 | $143.97 | -85.41% | 10 | Nov 10, 2025 | |
| AMGN Amgen | Reiterated: Sell | $272 | $377.35 | -27.92% | 15 | Nov 5, 2025 | |
| BIIB Biogen | Reiterated: Hold | $167 | $217.15 | -23.09% | 12 | Nov 3, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Hold | $50 → $52 | $63.64 | -18.29% | 18 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $543 → $627 | $781.49 | -19.77% | 14 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $28 → $30 | $27.72 | +8.23% | 34 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $140 | $143.72 | -2.59% | 17 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $198 → $204 | $265.58 | -23.19% | 15 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 11,500p | 11,708p | n/a | 1 | Feb 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | €102.00 → €105.00 | €73.26 | n/a | 2 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $52.75 | n/a | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | CHF 84.00 → CHF 88.00 | CHF 112.04 | n/a | 2 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $137.16 | n/a | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | CHF 410.00 → CHF 430.00 | CHF 344.20 | n/a | 2 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $80 → $92 | $36.04 | n/a | 4 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $45 | $42.77 | n/a | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | 105,836p | 1,771p | n/a | 1 | Feb 7, 2018 |
AbbVie
Sep 8, 2026
Reiterated: Buy
Price Target: $248 → $282
Current: $257.12
Upside: +9.68%
Aardvark Therapeutics
Dec 18, 2025
Reiterated: Buy
Price Target: $25
Current: $5.29
Upside: +373.04%
Amylyx Pharmaceuticals
Dec 18, 2025
Reiterated: Buy
Price Target: $16 → $15
Current: $31.62
Upside: -52.56%
Mineralys Therapeutics
Dec 18, 2025
Reiterated: Buy
Price Target: $43 → $46
Current: $29.34
Upside: +56.78%
Eli Lilly and Company
Dec 1, 2025
Reiterated: Buy
Price Target: $950 → $1,286
Current: $1,115.70
Upside: +15.26%
Merck & Co.
Nov 17, 2025
Reiterated: Buy
Price Target: $98 → $105
Current: $143.93
Upside: -27.05%
Moderna
Nov 10, 2025
Reiterated: Sell
Price Target: $24 → $21
Current: $143.97
Upside: -85.41%
Amgen
Nov 5, 2025
Reiterated: Sell
Price Target: $272
Current: $377.35
Upside: -27.92%
Biogen
Nov 3, 2025
Reiterated: Hold
Price Target: $167
Current: $217.15
Upside: -23.09%
Bristol-Myers Squibb Company
Nov 3, 2025
Reiterated: Hold
Price Target: $50 → $52
Current: $63.64
Upside: -18.29%
Oct 29, 2025
Reiterated: Sell
Price Target: $543 → $627
Current: $781.49
Upside: -19.77%
Oct 22, 2025
Reiterated: Hold
Price Target: $28 → $30
Current: $27.72
Upside: +8.23%
Oct 17, 2025
Reiterated: Buy
Price Target: $140
Current: $143.72
Upside: -2.59%
Oct 15, 2025
Reiterated: Hold
Price Target: $198 → $204
Current: $265.58
Upside: -23.19%
Feb 19, 2024
Reiterated: Buy
Price Target: 11,500p
Current: 11,708p
Upside: n/a
Jan 3, 2024
Upgraded: Buy
Price Target: €102.00 → €105.00
Current: €73.26
Upside: n/a
Jan 3, 2024
Downgraded: Hold
Price Target: n/a
Current: $52.75
Upside: n/a
May 9, 2022
Downgraded: Hold
Price Target: CHF 84.00 → CHF 88.00
Current: CHF 112.04
Upside: n/a
May 9, 2022
Downgraded: Hold
Price Target: n/a
Current: $137.16
Upside: n/a
Dec 29, 2021
Reiterated: Buy
Price Target: CHF 410.00 → CHF 430.00
Current: CHF 344.20
Upside: n/a
Nov 1, 2021
Reiterated: Buy
Price Target: $80 → $92
Current: $36.04
Upside: n/a
Feb 8, 2018
Reiterated: Hold
Price Target: $45
Current: $42.77
Upside: n/a
Feb 7, 2018
Reiterated: Hold
Price Target: 105,836p
Current: 1,771p
Upside: n/a